Prolonged survival of mice with established intracerebral glioma receiving combined treatment with peroxisome proliferator-activated receptor-γ thiazolidinedione agonists and interleukin-2-secreting syngeneic/allogeneic fibroblasts

Journal of Neurosurgery

Volumn 106, Issue 2, 2007, Pages 299-305

  Spagnolo, Alessandra ^a   Glick, Roberta P ^a   Lin, Henry ^a   Cohen, Edward P ^a   Feinstein, Douglas L ^a   Lichtor, Terry ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Glioma; Immunotherapy; Interleukin 2; Oxidative stress; Thiazolidinedione

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; INTERLEUKIN 2; LACTATE DEHYDROGENASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; SUPEROXIDE; SUPEROXIDE DISMUTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME RELEASE; FIBROBLAST; GLIOMA; GLIOMA CELL; IN VITRO STUDY; INCUBATION TIME; ISOGRAFT; METABOLIC STRESS; MONOTHERAPY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; FIBROBLASTS; GLIOMA; INTERLEUKIN-2; MICE; MICE, INBRED C57BL; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 33846842322     PISSN: 00223085     EISSN: 00223085     Source Type: Journal    
DOI: 10.3171/jns.2007.106.2.299     Document Type: Article

References (45)

1. Ahmad IM, Aykin-Burns N, Sim JE, Walsh SA, Higashikubo R, Buettner GR, et al: Mitochondrial O2*- and H2O2 mediate glucose deprivation-induced stress in human cancer cells. J Biol Chem 280:4254-4263, 2005
2. Berge K, Tronstad KJ, Flindt EN, Rasmussen TH, Madsen L, Kristiansen K, et al: Tetradecylthioacetic acid inhibits growth of rat glioma cells ex vivo and in vivo via PPAR-dependent and PPAR-independent pathways. Carcinogenesis 22:1747-1755, 2001
3. Chattopadhyay N, Singh DP, Heese O, Godbole MM, Sinohara T, Black PM, et al: Expression of peroxisome proliferator-activated receptors (PPARS) in human astrocytic cells: PPARgamma agonists as inducers of apoptosis. J Neurosci Res 61:67-74, 2000
4. Dello Russo C, Gavrilyuk V, Weinberg G, Almeida A, Bolanos JP, Palmer J, et al: Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes. J Biol Chem 278:5828-5836, 2003
5. Demetri GD, Fletcher CD, Mueller E, Sarraf P, Naujoks R, Campbell N, et al: Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A 96:3951-3956, 1999
6. Dionisi O, Galeotti T, Terranova T, Azzi A: Superoxide radicals and hydrogen peroxide formation in mitochondria from normal and neoplastic tissues. Biochim Biophys Acta 403:292-300, 1975
7. Feinstein DL: Contrasting the neuroprotective and gliotoxic effects of PPARg agonists. Drug Discov Today Ther Strategy 1:29-34, 2004
8. Feinstein DL: Therapeutic potential of peroxisome proliferator-activated receptor agonists for neurological disease. Diabetes Technol Ther 5:67-73, 2003
9. Fridovich I: Superoxide radical and superoxide dismutases. Annu Rev Biochem 64:97-112, 1995
10. Fujimura S, Suzumiya J, Nakamura K, Ono J: Effects of troglitazone on the growth and differentiation of hematopoietic cell lines. Int J Oncol 13:1263-1267, 1998
11. Galea E, Reis DJ, Feinstein DL: Cloning and expression of inducible nitric oxide synthase from rat astrocytes. J Neurosci Res 37:406-414, 1994
12. Gelman L, Fruchart JC, Auwerx J: An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. Cell Mol Life Sci 55:932-943, 1999
13. Griffitt W, Glick RP, Lichtor T, Haughton DE, Cohen EP: Development of a new mouse brain tumor model using implantable micro-cannulas. J Neurooncol 41:117-120, 1999
14. Grommes C, Landreth GE, Heneka MT: Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol 5:419-429, 2004
15. Grommes C, Landreth GE, Schlegel U, Heneka MT: The non-thiazolidinedione tyrosine-based peroxisome proliferator-activated receptor gamma ligand GW7845 induces apoptosis and limits migration and invasion of rat and human glioma cells. J Pharmacol Exp Ther 313:806-813, 2005
16. Henry RR: Thiazolidinediones. Endocrinol Metab Clin North Am 26:553-573, 1997
17. Kato M, Nagaya T, Fujieda M, Saito K, Yoshida J, Seo H: Expression of PPARgamma and its ligand-dependent growth inhibition in human brain tumor cell lines. Jpn J Cancer Res 93:660-666, 2002
18. Kim JA, Park KS, Kim HI, Oh SY, Ahn Y, Oh JW, et al: Troglitazone activates p21Cip/WAF1 through the ERK pathway in HCT15 human colorectal cancer cells. Cancer Lett 179:185-195, 2002
19. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, et al: Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 58:3344-3352, 1998
20. Lake RA, Robinson BW: Immunotherapy and chemotherapy - a practical partnership. Nat Rev Cancer 5:397-405, 2005
21. Lichtor T, Glick RP: Cytokine immuno-gene therapy for treatment of brain tumors. J Neurooncol 65:247-259, 2003
22. Lichtor T, Glick RP, Tarlock K, Moffett S, Mouw E, Cohen EP: Application of interleukin-2-secreting syngeneic/allogeneic fibroblasts in the treatment of primary and metastatic brain tumors. Cancer Gene Ther 9:464-469, 2002
23. Liu DC, Zang CB, Liu HY, Possinger K, Fan SG, Elstner E: A novel PPAR alpha/gamma dual agonist inhibits cell growth and induces apoptosis in human glioblastoma T98G cells. Acta Pharmacol Sin 25:1312-1319, 2004
24. Maeshiba Y, Kiyota Y, Yamashita K, Yoshimura Y, Motohashi M, Tanayama S: Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. Arzneimittelforschung 47:29-35, 1997
25. Marklund SL, Westman NG, Lundgren E, Roos G: Copper- and zinc-containing superoxide dismutase, manganese-containing superoxide dismutase, catalase, and glutathione peroxidase in normal and neoplastic human cell lines and normal human tissues. Cancer Res 42:1955-1961, 1982
26. Morosetti R, Servidei T, Mirabella M, Rutella S, Mangiola A, Maira G, et al: The PPARgamma ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines. Int J Oncol 25:493-502, 2004
27. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, et al: Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1:465-470, 1998
28. Na HK, Surh YJ: Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands as bifunctional regulators of cell proliferation. Biochem Pharmacol 66:1381-1391, 2003
29. Okura T, Nakamura M, Takata Y, Watanabe S, Kitami Y, Hiwada K: Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells. Eur J Pharmacol 407:227-235, 2000
30. Palakurthi SS, Aktas H, Grubissich LM, Mortensen RM, Halperin JA: Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res 61:6213-6218, 2001
31. Perez-Ortiz JM, Tranque P, Vaquero CF, Domingo B, Molina F, Calvo S, et al: Glitazones differentially regulate primary astrocyte and glioma cell survival. Involvement of reactive oxygen species and peroxisome proliferator-activated receptor-gamma. J Biol Chem 279:8976-8985, 2004
32. Posch MG, Zang C, Mueller W, Lass U, von Deimling A, Elstner E: Somatic mutations in peroxisome proliferator-activated receptor-gamma are rare events in human cancer cells. Med Sci Monit 10:BR250-BR254, 2004
33. Qin C, Burghardt R, Smith R, Wormke M, Stewart J, Safe S: Peroxisome proliferator-activated receptor gamma agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells. Cancer Res 63:958-964, 2003
34. Saltiel AR, Olefsky JM: Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:1661-1669, 1996
35. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, et al: Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 4:1046-1052, 1998
36. Strakova N, Ehrmann J, Bartos J, Malikova J, Dolezel J, Kolar Z: Peroxisome proliferator-activated receptors (PPAR) agonists affect cell viability, apoptosis and expression of cell cycle related proteins in cell lines of glial brain tumors. Neoplasma 52:126-136, 2005
37. Strakova N, Ehrmann J, Dzubak P, Bouchal J, Kolar Z: The synthetic ligand of peroxisome proliferator-activated receptorgamma ciglitazone affects human glioblastoma cell lines. J Pharmacol Exp Ther 309:1239-1247, 2004
38. Sugimura A, Kiriyama Y, Nochi H, Tsuchiya H, Tamoto K, Sakurada Y, et al: Troglitazone suppresses cell growth of myeloid leukemia cell lines by induction of p21WAF1/CIP1 cyclin-dependent kinase inhibitor. Biochem Biophys Res Commun 261:833-837, 1999
39. Tontonoz P, Hu E, Spiegelman BM: Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79:1147-1156, 1994
40. Tsubouchi Y, Sano H, Kawahito Y, Mukai S, Yamada R, Kohno M, et al: Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun 270:400-405, 2000
41. Van Driel BE, Van Noorden CJ: Oxygen insensitivity of the histochemical assay of glucose-6-phosphate dehydrogenase activity for the discrimination between nonmalignant and malignant cells. J Histochem Cytochem 47:575-582, 1999
42. Yin F, Bruemmer D, Blaschke F, Hsueh WA, Law RE, Herle AJ: Signaling pathways involved in induction of GADD45 gene expression and apoptosis by troglitazone in human MCF-7 breast carcinoma cells. Oncogene 23:4614-4623, 2004
43. Yin XY, Lu MD, Liang LJ, Lai JM, Li DM, Kuang M: Systemic chemo-immunotherapy for advanced-stage hepatocellular carcinoma. World J Gastroenterol 11:2526-2529, 2005
44. Zander T, Kraus JA, Grommes C, Schlegel U, Feinstein D, Klockgether T, et al: Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARgamma. J Neurochem 81:1052-1060, 2002
45. Zang C, Wachter M, Liu H, Posch MG, Fenner MH, Stadelmann C, et al: Ligands for PPARgamma and RAR cause induction of growth inhibition and apoptosis in human glioblastomas. J Neurooncol 65:107-118, 2003